Bristol Myers Squibb’s history is steeped in medical innovation, and its cardiovascular portfolio is no exception. The company’s legacy spans over 70 years of groundbreaking work, from pioneering ...

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place this week ...

I am interested in knowing how long it might take for someone who discontinued all medications that have been taken for years to have serious or dire ...

Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced Laura J. Seplavy, MS, joins its team as ...

DANBURY, Conn., Oct. 30, 2024 /PRNewswire/ -- Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance(1) for both Revenues and Adjusted(2) diluted EPS ...

and Apixaban (Eliquis).” Aspirin, a pretty common medication, is an antiplatelet, which prevents platelets from clumping together to form a clot and is often prescribed to people who have had a heart ...

For CrCl ≤15 mL/min, CKD stage V, no data available for any of the agents listed. ARISTOTLE indicates Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; bw, body ...